-
Biogen’s Litifilimab Shows Promise: New Phase 2 Data in Lupus Treatment
NASDAQ: $BIIB A Potential Breakthrough for Lupus Patients Biogen has recently shared encouraging updates regarding litifilimab, an investigational humanized monoclonal antibody currently being studied for the treatment of Systemic Lupus Erythematosus (SLE). New data presented from a 52-week Phase 2 study highlights the drug’s potential to offer both rapid and durable efficacy for those managing…